Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.05 USD
Change Today +0.07 / 1.41%
Volume 70.5K
ALQA On Other Exchanges
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

alliqua biomedical inc (ALQA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/6/14 - $7.20
52 Week Low
10/28/14 - $3.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alliqua biomedical inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua biomedical inc (ALQA) Details

Alliqua BioMedical, Inc. provides wound care solutions. The company offers Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through its direct sales force; and an independent network of agents. The company is headquartered in Langhorne, Pennsylvania.

50 Employees
Last Reported Date: 05/14/15

alliqua biomedical inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $682.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $376.8K
Chief Operating Officer
Total Annual Compensation: $376.8K
Compensation as of Fiscal Year 2014.

alliqua biomedical inc (ALQA) Key Developments

Alliqua Biomedical, Inc. Obtains Senior Secured Term Loan

Alliqua BioMedical, Inc. announced that it has obtained a Senior Secured Term Loan from Perceptive Advisors in the principal amount of $15.5 million to finance the initial cash purchase price of the acquisition.

Alliqua BioMedical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Revenue Guidance for the Year Ending December 31, 2015

Alliqua BioMedical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue, net of returns, allowances and discounts was of $2,113,564 compared to $590,575 a year ago. Loss from operations were of $7,676,766 compared to $8,753,650 a year ago. Loss before income tax provision was of $7,658,757 compared to $9,032,662 a year ago. Net loss was $7,661,592 or $0.48 per basic and diluted share compared to $9,036,162 or $0.73 per basic and diluted share a year ago. Non-GAAP net loss was $3.354 million or $0.21 per diluted share compared to $3.418 million or $0.28 per diluted share a year ago. The Company is maintaining its revenue guidance for the fiscal year 2015 period, which was last updated on April 23rd, 2015. The Company's revenue guidance reflects the expected incremental contributions from the acquisition of Celleration, based on a closing date of May 29th. For the fiscal year ending December 31, 2015, the Company expects total revenue of $16.3 million to $18.8 million, representing growth at the mid-point of the range of approximately 267% year-over-year.

Alliqua BioMedical, Inc. to Report Q1, 2015 Results on May 14, 2015

Alliqua BioMedical, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 14, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $5.05 USD +0.07

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Derma Sciences Inc $6.65 USD +0.02
MiMedx Group Inc $10.13 USD -0.24
Osiris Therapeutics Inc $18.66 USD +0.15
Smith & Nephew PLC 1,155 GBp -6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA BIOMEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at